TANAMIN Digital Health Challengeのパートナーシッププログラムの成果発表会を開催〜日比谷国際ビルコンファレンススクエア8F
Tanamin Digital Health Challenge

Application Deadline: 2022.9.16 1AM PST / Launch event 2022.7.28 5pm PST / Investor Day 2023.3.M

Startup Corporate Partnership Program
in Digital Health field


たなみんMitsubishi Chemical Group Corporation (MCG) seeks to collaborate with startups in order to adopt novel technologies in healthcare that will improve the quality of life of patients and their families. The 6 months online program will connect startups to the project teams of Mitsubishi Tanabe Pharma Corporation (MTPC), in an effort to work toward mutually agreed upon goals. In addition to industry focused seminars and mentoring, selected program participants will receive a non-dilutive program participation prize of 2.5M Yen.


  • 1.
  • An opportunity to perform a paid Proof of Concept (PoC) project with MCG and explore follow-on partnerships like joint development licensing agreements, manufacturing collaborations, and more with MCG and its operating companies, and/or investment from MCG’s CVC arm, Diamond Edge Ventures

  • 2.
  • 2.5M Yen* in non-dilutive grant funding to cover the cost of the PoC.
    *Funding required beyond 2.5M Yen may be available and will be evaluated on a case-by-case basis.

  • 3.
  • Access to the Plug and Play and MCG networks

  • 4.
  • Mentorship, networking opportunities, and partnership-focused workshops from the Plug and Play community of healthcare startup experts

  • 5.
  • Opportunity to pitch in front of prominent investors of digital health ecosystem on investor day

PROGRAM (themes)

Improve well-being of ALS patients and their families
Program #1

Improve well-being of ALS patients and their families

ALS is a neurodegenerative disease that results in loss of the ability to eat, speak, move, and finally breathe, leading to early death from respiratory failure. It takes 1-2 years for ALS patients to get diagnosis because most of the patients do not initially reach out to the specialists resulting in delay in the start of treatment. ALS is also intractable, making it difficult for patients to maintain their motivation for the continuation of the treatment. During TANAMIN Digital Health Challenge, the goal is to raise awareness in the community to reach out the right doctor at earliest possible signs of ALS. Also, we aim to improve the well-being of ALS patients, their families and loved ones using digital technologies. We are looking for startups with the following digital tools:

  • Digital technologies to increase awareness and encourage patients to get early diagnostics
  • Development of medication support applications e.g., medication guidance, medication management to improve adherence, nutritional management, daily activity monitoring
  • Digital technologies that provide a supportive environment for interaction among ALS patients themselves and family members of ALS patients
  • Digital technologies to enable patients with impaired conversational function to communicate more effectively

Selected startups will be working with the MTPC team, a pharmaceutical company focused on providing options for ALS patients in Japan and in the United States, among many other diseases. Thus, startups will have great opportunity to create difference in the life of ALS patients and in their families.

Eligibility criteria: Startups with working prototypes ready to be used for paid proof of concept study. The initial PoC will target the Japanese market, with the possibility of expanding to the global market after a successful PoC.

Digitalize Decentralized Clinical Trial
Program #2

Digitalize Decentralized Clinical Trial (DCT)

Recently decentralized clinical trials (DCT) are getting a lot of attention. Decentralization often presents challenge of remote patient monitoring or obtaining biological samples, and currently, nurse’s home visits are arranged to overcome these challenges. However, nurse’s home visit also has the other challenges such as travel burden of research staff, restrictions of local law etc.. During TANAMIN Digital Health Challenge, we are looking for technologies required for general clinical trials irrespective of the indication or therapeutic product that can replace or minimize nurse’s visits. More specifically;

  • Medical devices or technologies that would allow patients to collect biological samples on their own without outpatient visits or intervention of medical professional.
  • Digital health devices or technologies that allows remote patient monitoring but obtain data with similar quality required for clinical trials.

Eligibility criteria: Startups with technologies already approved or expected to be approved within a few years by relevant regulatory authorities. Startups with cutting edge technologies under development can apply but must have devices at design freeze stage and have human data sets available using those tools.

Increase preventative vaccination in Japan
Program #3

Increase preventative vaccination in Japan

Vaccines play very important role in preventive care. In Japan, the coverage of routine childhood vaccines is high, but the coverage of voluntary vaccination in child and adults is extremely low despite the availability of local government subsidies for certain vaccines. In TANAMIN Digital Health Challenge, we would like to leverage digital technology of promising startups to improve voluntary vaccination coverage. We are looking for startups with the following tools:

  • Adapting proven digital technology tools that engage, retain, and change behavior towards preventive care especially vaccination.
  • Can propose digital solution to increase the coverage of voluntary vaccination. For example,
    • startups that can simplify vaccination reservation system
    • startups having platform with a Japanese customer contact data base of consumer over 50s.(e.g. on-line medical service,. Medical platform with nursing care and nursing service)
  • Startups that can capture data related to in-hospital prescriptions of voluntary and routine vaccines.(e.g. Digital vaccine pre-medication form)
  • Digital technology tools that improve the convenience of stakeholders related to vaccination

Eligibility criteria:
Startups with existing tools developed for other applications but can be used for above purposes. Startups with tools for vaccines ready to do a feasibility study. There is a possibility of involvement of local Japanese governments during or after successful feasibility study so startups who can understand and speak Japanese would be preferred.

The initial PoC will be targeted to the Japanese market for herpes vaccine, but scope can be expanded to other vaccine and geographies


  • Submit a completed application via the online portal by August 31, 2022.
  • Be available for virtual and/or in-person interviews if selected for further rounds after the first round application deadline.
  • Do not submit confidential information with your application.
  • Winners will sign a confidentiality agreement to protect their IP for the duration of the TANAMIN digital health challenge.


  • Application period

    June 29th , 2022 –
    Sep. 16th , 2022

  • >
  • Selection period

    Sep. 17th , 2022 –
    Oct. 31st 2022

  • >
  • Paid PoC period

    Nov 1st , 2022 –
    Feb 28th 2023

  • >
  • Investor Day

    Mid-Mar, 2023



Q: How much time commitment is required for the program?

A. Mandatory seminars and events will be limited to 5-10 hours throughout the 6 months program and the rest will be driven by mutually agreed goals between the startups and MCG.

Q: How many startups will be selected for the program?

A. 1-2 startup will be selected for each theme.

Q: Will investments be provided to the selected startups?

A. Investment will not be automatically provided to the selected startups, nevertheless it may be considered during the course of the program and after the successful completion of the PoC.

Q: Do I need to physically travel for the program?

The program will be held online but the startups may be invited to optional offline events and meetings.

・About Mitsubishi Chemical Group Corporation (MCG)

Mitsubishi Chemical Group Corporation conducts its corporate activities and businesses worldwide in the domains of Performance Products, Industrial Materials, and Health Care based on the core values of “Sustainability,” “Health,” and “Comfort.” The company builds stakeholder value while contributing to the sustainable well-being of people, society and our planet Earth.

・About MCG Corporate Venturing

MCG has established a global venture capital team in Tokyo, Japan and Silicon Valley, California to create new business opportunities across the MCG through strategic partnerships with promising startups. Since the establishment in 2018, Corporate venturing team has facilitated more than 200 collaborations between startups and MCG’s business units or R&D centers . Also, Corporate venturing team has invested directly in 9 startups worldwide. The KAITEKI Challenge, a Startup-Corporate Partnership Program with similar concept focused on the Circular Economy, was launched in 2020. This is the second instantiation of MCG’s startup-corporate partnership program after the successful KAITEKI Challenge. We continue to offer strong and sustainable support to the success of our startup partners.

・About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group Corporation (MCG Group), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. The MCG Group has positioned health care as its strategic focus in its management policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is prioritizing work on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety, focusing on the disease areas of central nervous system and immuno-inflammation. In addition, MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to https://www.mt-pharma.co.jp/e/